AstraZeneca PLC (AZN)vsNewmont Goldcorp Corp (NEM)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
NEM
Newmont Goldcorp Corp
$101.52
+2.52%
BASIC MATERIALS · Cap: $108.06B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 159% more annual revenue ($58.74B vs $22.67B). NEM leads profitability with a 31.2% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.50. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
NEM
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
-184.1%
Fair Value
$43.86
Current Price
$101.52
$57.66 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 58.1%
Conservative balance sheet, low leverage
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Earnings declined 4.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : NEM
The strongest argument for NEM centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 31.2% and operating margin at 58.1%. Revenue growth of 20.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : NEM
The primary concerns for NEM are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a value stock while NEM is a growth play — different risk/reward profiles.
NEM carries more volatility with a beta of 0.39 — expect wider price swings.
NEM is growing revenue faster at 20.6% — sustainability is the question.
NEM generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (66/100 vs 65/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Newmont Goldcorp Corp
BASIC MATERIALS · GOLD · USA
Newmont Corporation, based in Greenwood Village, Colorado, United States, is one of the largest gold mining companies in the world.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?